In the present study, AME treatment enhanced FGF21-dependent SIRT1/PGC1α pathways in the liver and skeletal muscle, although the markers were selectively modulated with different treatment doses in T2DM mice. Here, PPARGC1A is linked to type 2 diabetes mellitus.